FLASH 002
Alternative Names: FLASH-002Latest Information Update: 31 Mar 2025
At a glance
- Originator Flashpoint Therapeutics
- Class Antineoplastics; Immunotherapies; Oligonucleotides
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cervical cancer; Head and neck cancer
Most Recent Events
- 12 Mar 2025 Preclinical trials in Cervical cancer in USA (Parenteral) (Flashpoint Therapeutics pipeline, March 2025)
- 12 Mar 2025 Preclinical trials in Head and neck cancer in USA (Parenteral) (Flashpoint Therapeutics pipeline, March 2025)